GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (STU:5GH) » Definitions » EV-to-FCF

Guardant Health (STU:5GH) EV-to-FCF : -17.59 (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Guardant Health EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Guardant Health's Enterprise Value is €4,433.0 Mil. Guardant Health's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-252.0 Mil. Therefore, Guardant Health's EV-to-FCF for today is -17.59.

The historical rank and industry rank for Guardant Health's EV-to-FCF or its related term are showing as below:

STU:5GH' s EV-to-FCF Range Over the Past 10 Years
Min: -119.88   Med: -37.66   Max: -6.46
Current: -16.98

During the past 8 years, the highest EV-to-FCF of Guardant Health was -6.46. The lowest was -119.88. And the median was -37.66.

STU:5GH's EV-to-FCF is ranked worse than
100% of 97 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.45 vs STU:5GH: -16.98

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), Guardant Health's stock price is €33.30. Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-3.887. Therefore, Guardant Health's PE Ratio (TTM) for today is At Loss.


Guardant Health EV-to-FCF Historical Data

The historical data trend for Guardant Health's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health EV-to-FCF Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -101.33 -76.16 -37.39 -8.14 -10.06

Guardant Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.17 -10.06 -9.08 -12.89 -11.54

Competitive Comparison of Guardant Health's EV-to-FCF

For the Diagnostics & Research subindustry, Guardant Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Guardant Health's EV-to-FCF falls into.



Guardant Health EV-to-FCF Calculation

Guardant Health's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4433.032/-252.005
=-17.59

Guardant Health's current Enterprise Value is €4,433.0 Mil.
Guardant Health's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-252.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardant Health  (STU:5GH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Guardant Health's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=33.30/-3.887
=At Loss

Guardant Health's share price for today is €33.30.
Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.887.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Guardant Health EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Guardant Health's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health Headlines

No Headlines